Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

End of Dose Phenomena in Subcutaneous Natalizumab Treated MS Patients

NCT05701423 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT05701423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05701423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
End of Dose Phenomena in Subcutaneous Natalizumab Treated MS Patients
Lead sponsor
Biogen
Phase
Observational
Overall status
Terminated
Start date
February 8, 2023
Completion date
July 31, 2024
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis